Page 170 - CW E-Magazine (11-2-2025)

News from Abroad

EXPANSION
AGC Pharma Chemicals boosts HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a contract “Our integrated approach represents
development and manufacturing organi- AGC’s commitment to supporting the
sation (CDMO) for small molecule APIs complete HPAPI development jour-
and part of Japan’s AGC Group, has ney. By offering an uninterrupted chain
announced a signifi cant expansion of of capabilities together, we enable our
its High Potency Active Pharmaceutical partners to advance their high-potency
Ingredients (HPAPI) capabilities, enabling compounds from initial grams through
seamless scale-up from grams to tons commercial tons, all within a single,
within a single integrated ecosystem. trusted ecosystem”.

This expansion in Barcelona ad- that seamlessly connects early-phase The HPAPI chain in Barcelona
dresses the growing demand for HPAPI development through commercial manu- includes:
driven by advances in oncology, targe- facturing. As a CDMO with HPAPI  A new R&D laboratory, opera-
ted therapies, and personalised medi- capabilities from gram to tons, AGC tional from March 2025, featuring
cine, where highly potent compounds has systematically adapted its entire advanced OEB5 containment systems.
are essential for developing more pre- development and manufacturing chain  New IPC/QC laboratories, opera-
cise and effective treatments. The global to OEB5 standards (0.1–1 µg/m³ over tional from March 2025, supporting
HPAPI market valued at $25.38-bn in an 8-hour shift), from its new R&D all development phases.
2024 is projected to reach $47.44-bn by facility through laboratory to commercial  Multi-purpose existing kilolab
2031, growing at a CAGR of 8.13. production, ensuring consistent con- facilities equipped with OEB5
tainment capabilities throughout the containment systems.
This strategic enhancement com- entire process.  New manufacturing facility (opera-
pletes AGC Pharma Chemicals’ end- tional second half of 2025) with
to-end HPAPI capabilities, establishing Mr. Akihiro Kadokura, CEO of an OEB5 HPAPI bay with reactors
a fully integrated containment solution AGC Pharma Chemicals, commented, volumes of 1.5 m³.

ENSURING CIRCULARITY
Dow partners Italian fi rms to turn imperfect perfume caps

into luxury footwear

Dow has announced a collaboration ing an opportunity in the luxury goods
with Italian cosmetics packaging spe- industry and demonstrating the importance
cialist, Brivaplast, and Italian footwear of working together across the materials
fi rm, TecnoGi, to advance circularity in value chain to promote circularity.
the luxury goods industry. This initia-
tive will reprocess imperfect perfume requires stringent quality standards, “Our collaboration with Brivaplast
caps for use in luxury footwear and which occasionally results in the pro- and TecnoGi comes at a time when
leather goods, reducing manufacturing duction of substandard pieces. To pro- demand for sustainable materials and
scrap and enhancing value across vide a new life to this post-industrial packaging solutions continues to grow.
multiple sectors. scrap, TecnoGi will reprocess these We’re proud to show what can be
imperfect perfume caps for use in high- achieved by working together across
Dow currently supplies Surlyn end components for luxury footwear the value chain, and the benefi ts for
branded resin to Brivaplast for mak- and leather goods. all of keeping valuable materials in
ing fl awless, gem-like perfume caps the loop for longer,” said Mr. Imran
for prestigious fragrance brands. The By reusing these materials, Dow, Munshi, Global Consumer Market Seg-
production of luxury perfume caps Brivaplast, and TecnoGi are highlight- ment Leader at Dow.

170 Chemical Weekly February 11, 2025

Contents Index to Advertisers Index to Products Advertised